CE1 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO SITAGLIPTIN AND SAXAGLIPTIN BASED ON CARDIOVASCULAR OUTCOME TRIALS | Publicación